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Abstract In light of the need for new antifungals, we
compared the in vitro antifungal activity of two peptides
derived from human lactoferrin (hLF), i.e., hLF(1–11) and
hLF(21–31), two analogs of histatin 5, further referred to as
dhvar4 and dhvar5, and two ubiquicidin (UBI)-derived
peptides, i.e., UBI 18–35 and UBI 29–41, with that of
amphotericin B against Aspergillus fumigatus hyphae using
the MTT assay. The results revealed a dose-dependent
antifungal activity for all peptides, with dhvar5 being the
most potent peptide. In addition, hLF(1–11), dhvar5, and
UBI 18–35 were effective against A. fumigatus conidia.
Furthermore, hLF(1–11) did not lyze human erythrocytes,
whereas dhvar5 (≥16 μM) and UBI 18–35 (≥20 μM) were
hemolytic. Based on these in vitro results and their
effectiveness against infections in mice, we concluded that
hLF(1–11) and dhvar5 are promising candidates for the
development of new agents against A. fumigatus infections.
Introduction
A large surveillance in the United States from 1980 through
1997 revealed that, of the deaths in which an infectious
disease was the underlying cause, the mortality due to
invasive mycoses increased from the tenth most common
cause in 1980 to the seventh most common in 1997, with an
impressive 3.6-fold increase in mortality associated with
aspergillosis [1]. Furthermore, a systematic review of the
literature revealed a case–fatality rate of 58% for patients
with invasive aspergillosis and was especially high in bone
marrow transplant recipients (87%) [2]. Moreover, ampho-
tericin B deoxycholate and lipid formulations thereof failed
to prevent death in one-half to two-thirds of these patients
[2]. Despite the introduction of several new antifungals
(newer generation azoles and echinocandins), the mortality
and morbidity of aspergillosis is still high [2, 3].
The availability of effective strategies to improve the
outcome for patients with opportunistic mycoses, in
particular, invasive aspergillosis, constitutes an enormous
medical need and antimicrobial peptides [4–6] may be
promising candidates for this purpose because their mech-
anisms of action differ from that of current antifungals and
the acquisition of resistant mutants is less likely to occur.
An interesting approach is the use of synthetic peptides
derived from natural antimicrobial proteins/peptides with
antifungal activities. For example, human lactoferrin (hLF),
which is a protein synthesized and released by activated
neutrophils and mucosal epithelial cells, exerted antifungal
activities. This antimicrobial protein contains two cationic
domains in its N terminus. A recent study indicated that a
synthetic peptide including the first cationic domain, further
referred to as hLF(1–11), is more effective in killing
Candida albicans than the native protein or a peptide,
hLF(21–31), comprising the second cationic domain [7].
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Moreover, the hLF(1–11) peptide is effective against an
invasive infection with fluconazole-resistant C. albicans in
mice [6]. Histatin 5 is a histidine-rich, cationic peptide
secreted by human parotid and submandibular glands [8].
From this peptide, several analogs with antifungal activi-
ties, further referred to as dhvar4 and dhvar5, have been
designed [9]. Furthermore, our research has focused on
ubiquicidin, a 6,648-Da linear cationic antimicrobial pep-
tide produced by IFN-γ-activated murine macrophages and
human airway epithelial cells [10]. This peptide displays
antimicrobial activity against a variety of bacteria and C.
albicans species. Recently, synthetic peptides derived from
ubiquicidin, e.g., UBI 18–35, and UBI 29–41, have been
selected on the basis of their antimicrobial activities [11]. In
a first attempt to select the most promising candidates, we
compared the in vitro antifungal activities of these six
synthetic antimicrobial peptides against Aspergillus fumi-
gatus and their hemolytic effects.
Materials and methods
Fungal strain and growth conditions
A. fumigatus (a clinical isolate) was cultured on potato
dextrose agar for 4 days at 30°C. A suspension of
conidia was prepared by the filtration of this culture and
washed twice in 10 mM sodium phosphate buffer
(NaPB; pH 7.4). In some experiments, the conidia were
used as described. However, in most experiments, hyphae
were studied. For this purpose, 5×104 colony-forming
conidia ml−1 of yeast nitrogen base (YNB) medium
supplemented with 2% glucose were cultured in flat-bottom
24-well plates for 15 h at 30°C until >95% of the conidia
had germinated.
Antimicrobial peptides
The synthetic peptides hLF(1–11) (GRRRRSVQWCA; Mw
1,374 Da), hLF(21–31) (FQWQRNMRKVR; Mw
1,567 Da), UBI 18–35 (KVAKQEKKKKKTGRAKRR;
2,169 Da), UBI 29–41 (TGRAKRRMQYNRR;
1,693 Da), and peptide 4 (part of gp120 from HIV-1;
RPVVSTQLLLNGSLAEEEVV; 2,171 Da) were prepared
and purified as described [7]. The peptides dhvar4
(KRLFKKLLFSLRKY; 1,841 Da) and dhvar5
(LLLFLLKKRKKRKY; 1,848 Da) were a kind gift from
Dr. W. van’t Hof (Academic Centre for Dentistry, Depart-
ment of Oral Biochemistry, Free University, Amsterdam,
the Netherlands). The purity of the various peptides ranged
from 88–97%, as determined by reverse-phase high-
performance liquid chromatography (RP-HPLC). The pep-
tides were stored and used as previously described [7].
Effects of peptides against A. fumigatus hyphae
using the MTT assay
To quantitate the antifungal activities of antimicrobial
peptides, adherent hyphae were washed twice in NaPB
before exposure for 1 h at 37°C to the various peptides.
Peptide 4 was used as the negative control and amphoter-
icin B as the positive control. Next, hyphae were washed
twice and the mass of viable A. fumigatus was quantitated
by a rapid colorimetric assay [12] using the tetrazolium salt
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide; MTT). Hyphal damage was calculated by comparing
the absorption by peptide-treated organisms with that from
untreated organisms using the following equation:
percentage of hyphal damage




where A is the absorbance at 570 nm.
For comparison of the antifungal effects of the various
antimicrobial peptides against A. fumigatus, we calculated
the concentration of the peptides at which 50% of the
maximal antifungal activity is reached by non-linear
regression with the dose–effect model according to the
following equation [13]:
E ¼ Emax  CEC50 þ C
where E is the observed antifungal effect at a given
concentration (C) of the peptide, Emax is the maximal
antifungal activity, and EC50 is the estimated concentration
of the peptide at which 50% of the maximal antifungal
activity is reached.
Effects of peptides against A. fumigatus conidia
using the AlamarBlue™ assay
To compare the effects of peptides against A. fumigatus
conidia, we determined their minimal inhibitory concen-
trations (MICs) as recommended by the National Commit-
tee for Clinical Laboratory Standards (NCCLS) using
AlamarBlue™ [14]. In short, 1 ml of a suspension of
approximately 1–2×103 conidia/ml of RPMI 1640 medium
with L-glutamine was pipetted together with 25 μl of
AlamarBlue™ into the wells of a 24-well plate and then the
various antimicrobial peptides or, as the control, no peptide
were added. After incubation for 72 h at 30°C, the color
change from dark blue to red was quantitated by measuring
the absorbance at 600 nm. The MIC was defined as the
minimal concentration of the antimicrobial peptide prevent-
ing the development of the red color.
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Hemolysis assay
We used a hemolysis assay to establish the cytotoxicity of
the different peptides. Briefly, freshly collected heparinized
blood from healthy individuals was centrifuged at 100g for
15 min. The erythrocytes were washed three times with
PBS, centrifuged at 1,000g for 10 min, and resuspended in
PBS to a concentration of 1% (v/v). Antimicrobial peptides
were serially diluted in PBS (range 1.56–600 μg/ml) and
100 μl thereof was added in triplicate to 100 μl of the
erythrocyte suspension. After incubation for 1 h at 37°C,
the mixtures were centrifuged at 1,000g for 5 min and 150 μl
of the supernatants were transferred to a flat-bottom 96-well
plate for measurement of the hemoglobin release by reading
the absorbance at 450 nm. PBS and 1% Tween-20 were used
to establish 0% and 100% hemolysis. The percentage of intact
erythrocytes was calculated using the following formula:




where Apeptide is the absorbance at 450 nm in the well
containing the peptide, APBS the absorbance at 450 nm in the
well to which PBS was added, and ATween is the absorbance
at 450 nm in the well containing Tween-20.
Statistical analyses
Differences between the values for cells exposed to
antimicrobial peptides and those exposed to peptide 4 were
analyzed using the Mann-Whitney U-test. The level of
significance was set at p<0.05.
Results
Antifungal activities of antimicrobial peptides
The results revealed a dose-dependent antifungal activity
against A. fumigatus hyphae for hLF(1–11) (R2=0.69;
p<0.05), hLF(21–31) (R2=0.99; p<0.05), dhvar4
(R2=0.83; p<0.05), dhvar5 (R2=0.87; p<0.05), UBI 18–
35 (R2=0.73; p<0.05), and UBI 29–41 (R2=0.95; p<0.05);
the control peptide 4 being ineffective (Fig. 1). The
maximum hyphal damage by the various antimicrobial
peptides amounted to 70–80%, which was similar to the
values for ≥0.1 nM amphotericin B. Comparison of the EC50
values for the various peptides revealed that dhvar5 (EC50=
3±1 μM) is the most potent peptide; the EC50 values for hLF
(1–11), hLF(21–31), dhvar4, UBI 18–35, and UBI 29–41
being 29±5 μM, 142±13 μM, 19±5 μM, 37±15 μM, and
91±19 μM, respectively. Notably, hLF(1–11) is 5-fold more
effective than hLF(21–31), dhvar5 is 6-fold more potent than
dhvar4, and UBI 18–35 is almost 3-fold more effective than
UBI 29–41 in damaging A. fumigatus hyphae. In agreement,
the MIC values for dhvar5, hLF(1–11), UBI 18–35, and
amphotericin B against A. fumigatus conidia amounted to
3.6±2.2 μM, 5±4 μM, 18±13 μM, and 2.2±0.8 μg/ml,
respectively (n=5–7).
Hemolytic activity of antimicrobial peptides
The peptides hLF(1–11) and UBI 29–41 did not lyze human
erythrocytes at concentrations ≥200 μM, whereas dhvar5,
hLF(21–31), and UBI 18–35 caused significant hemolysis









































Fig. 1 Hyphal damage of Aspergillus fumigatus by hLF(1–11), hLF
(21–31), dhvar4, dhvar5, UBI 18–35, UBI 29–41 peptides and
amphotericin B. Aspergillus fumigatus hyphae were exposed to
various concentrations of hLF(1–11), hLF(21–31), dhvar4, dhvar5,
UBI 18–35, and UBI 29–41 (solid bars), peptide 4 or no peptide
(open bars; negative controls) or amphotericin B (hatched bars;
positive control) for 1 h. Next, the mass of viable A. fumigatus was
quantitated by the MTT assay. Hyphal damage was calculated by
comparing the absorbance at 570 nm by peptide-treated organisms
with that by control organisms either untreated or treated with peptide
4. The results are shown as the means (plus standard deviation [SD])
of at least three independent experiments
Eur J Clin Microbiol Infect Dis (2008) 27:1125–1129 1127
(>2–3%) at ≥16 μM, ≥16 μM, and ≥20 μM, respectively. The
hemolytic activity of dhvar4 was not tested.
Discussion
The main conclusion from the present results is that hLF(1–
11) and dhvar5 are the most promising candidates for the
development of new agents to treat infections with A.
fumigatus. This conclusion is based on the following lines
of evidence.
First, dhvar5 and hLF(1–11) were among the most
potent peptides against A. fumigatus hyphae in vitro, and
they were also active against A. fumigatus conidia in vitro.
It should be realized that the antifungal activities of
antimicrobial peptides in vitro may not reflect their
antifungal activity in infected animals. For example, we
reported that the doses of hLF(1–11) required for antifungal
effects in mice with a disseminated C. albicans infection
were much lower than that required in in vitro experiments
[6]. Possible explanations for these observations include
synergistic/additive effects between this peptide and host-
derived antifungal factors, such as endogenous antimicro-
bial proteins/peptides and reactive oxygen intermediates
[6]. Furthermore, the hLF(1–11) peptide, and perhaps
dhvar5 as well, stimulates the antimicrobial activities of host
cells, e.g., human mononuclear phagocytes [15]. Second, at
the highest concentrations tested, no toxicity of hLF(1–11)
and UBI 29–41 on human erythrocytes has been observed,
while dhvar5 and hLF(21–31) caused significant hemolysis
at a concentration ≥16 μM and UBI 18–35 at a concentra-
tion ≥20 μM. Moreover, safety studies with hLF(1–11) in
laboratory animals and humans have been successfully
completed. Thirdly, all peptides under investigation dis-
played antibacterial activities against infections with, e.g.,
methicillin-resistant Staphylococcus aureus (MRSA) in
mice [11] and the hLF(1–11) peptide is effective against
an invasive C. albicans infection in mice [6]. Since both
hLF(1–11) and dhvar5 act synergistically in vitro with
current antifungal agents against Candida species [9, 16], it
may be expected that such combinations are also highly
effective against infections with A. fumigatus. If effective in
vivo, such combinations may reduce the dose and duration
of anti-infective agents and the use of multiple antibiotics,
thereby, limiting the emergence of drug-resistant strains.
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